Partnerships for Biodefense (R01) | Apply Online

Opportunity Summary:

The Partnerships for Biodefense (R01) opportunity (Funding Opportunity Number RFA-AI-11-014) is a discretionary grant program from the National Institute of Allergy and Infectious Diseases (NIAID) within the National Institutes of Health (NIH). It is designed to push biodefense-related medical countermeasures closer to real-world use by supporting preclinical development work on lead candidates. The focus is on vaccines, therapeutics, adjuvants, and diagnostics aimed at NIAID Category A, B, or C priority agents, which are the pathogens and threats NIAID considers most important from a biodefense and public health preparedness standpoint. In practical terms, this FOA is not meant for early exploratory science alone; it is oriented toward development activities that help a promising candidate move along the pipeline toward later-stage development, with an emphasis on product-like planning and execution.

A defining feature of this FOA is the partnership model. Applications are expected to involve meaningful participation from at least one industrial partner, and the application must demonstrate substantive investment by that industrial participant. That requirement signals that NIAID is looking for projects where industry is not merely a nominal collaborator, but is contributing real resources, capabilities, and commitment consistent with product development (for example, manufacturing know-how, assay development expertise, regulatory experience, scaled formulation work, quality systems, or other concrete contributions). In addition, applicants must include a Product Development Strategy attachment, which is intended to make the project plan look more like a translational development program than a conventional academic research plan. While the source text does not spell out the attachment contents, the intent is clear: NIAID wants a structured plan that lays out the development path for the candidate, key milestones, risks, and how the team will make go/no-go decisions as data accumulates.

The funding instrument is an R01 research project grant, and the activity areas align with NIH biodefense-relevant research domains under CFDA numbers 93.855 (Allergy, Immunology and Transplantation Research) and 93.856 (Microbiology and Infectious Diseases Research). The FOA indicates there is no cost sharing or matching requirement, meaning applicants are not formally required by the government to contribute matching funds as a condition of the award. However, the industrial investment requirement effectively serves a similar purpose by ensuring there is significant non-federal commitment supporting the proposed development effort, which can strengthen feasibility and readiness for later transition.

The estimated total funding associated with this opportunity is listed as $20,200,000. Key dates show it was posted and created on March 7, 2011, with an original and current closing date of May 27, 2011, and an archive date of June 27, 2011. Those dates place the announcement in a historical context, but the structure is still a useful reference for how NIAID frames partnered, preclinical biodefense development projects: development-focused scope, formalized product strategy, and tangible industry buy-in.

Eligibility is broad and includes a wide range of domestic and international organization types. Eligible applicants include nonprofit organizations (including those with and without 501(c)(3) status), public and private institutions of higher education, small businesses, for-profit organizations (including those other than small businesses), and multiple levels of government such as state, county, city or township, special district governments, independent school districts, and public housing authorities/Indian housing authorities. The FOA also explicitly includes categories such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and faith-based or community-based organizations, among others. Importantly, non-U.S. entities (foreign organizations), regional organizations, U.S. territories or possessions, and foreign components of U.S. organizations are allowed, which broadens the pool of potential applicants and partners for specialized biodefense capabilities that may exist outside the United States.

For applicants, the core takeaway is that NIAID is looking for preclinical-stage, lead-candidate programs that are organized around deliverables and a credible path toward a usable medical countermeasure, not just hypothesis-driven experimentation. Competitive proposals would be expected to clearly justify the target agent (Category A/B/C priority), describe the candidate and its differentiators, map the preclinical work needed to de-risk and advance it (such as proof-of-concept efficacy models, dosing and route optimization, safety/toxicology planning appropriate for preclinical development, development of reproducible assays and correlates, formulation stability, and other enabling studies), and present a realistic development timeline. Just as critically, they would need to show why the industry partner is essential to success and how that partner is concretely invested, since that is an explicit requirement of the announcement.

The sponsoring agency is NIH, with NIAID as the issuing institute. The announcement provides an additional information link to the full NIH Grants Guide posting (http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-11-014.html) and lists NIH Office of Extramural Research (OER) webmaster contacts for access or linking issues (FBOWebmaster@OD.NIH.GOV).

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Health

Next opportunity: Technology and Media Services for Individuals With Disabilities Steppingstones of Technology Innovation for Children With Disabilities (Phase 1) CFDA Number 84.327A

Previous opportunity: Egyptian Economic Support

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for RFA AI 11 014

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (RFA AI 11 014) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "RFA AI 11 014", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.